Acute renal insufficiency during telavancin therapy in clinical practice

Luis A. Marcos, Bernard C. Camins, David J. Ritchie, Ed Casabar, David K. Warren

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Objectives: To describe the tolerance to long-term telavancin therapy among inpatients as it relates to nephrotoxicity. Methods: Retrospective cohort study of adult patients who received telavancin at the Barnes-Jewish Hospital from 1 September 2009 to 1 December 2010. Patients who received less than three doses of telavancin, were on haemodialysis prior to telavancin administration or died within 48 h of initial telavancin administration were excluded. Results: Twenty-one patients received telavancin and met the inclusion criteria. Seven of 21 patients (33%) developed acute renal insufficiency during therapy. Patients who developed acute renal insufficiency had a mean glomerular filtration rate reduction of 56 mL/min/1.73 m 2. In the univariate analysis, high body mass index (P = 0.025), use of intravenous contrast dye (P = 0.017) and prior serum vancomycin trough levels >20 mg/L (P = 0.017) were associated with developing acute renal insufficiency. Two patients required haemodialysis; two had persistent renal insufficiency. Conclusions: Supratherapeutic vancomycin trough levels, high body mass index and receipt of intravenous contrast dye prior to telavancin therapy were associated with acute renal insufficiency.

Original languageEnglish
Article numberdkr518
Pages (from-to)723-726
Number of pages4
JournalJournal of Antimicrobial Chemotherapy
Issue number3
StatePublished - Mar 2012
Externally publishedYes


  • Daptomycin-non-susceptible S. aureus
  • Methicillin-resistant Staphylococcus aureus
  • Nephrotoxicity
  • Vancomycin-intermediate S. aureus


Dive into the research topics of 'Acute renal insufficiency during telavancin therapy in clinical practice'. Together they form a unique fingerprint.

Cite this